As early as 1987, Burchell et al. designed an mAb (SM3) against the PDTRP sequence on MUC1, which responded to 91% of BC, but showed little response to benign breast tumors, normal resting, pregnant or breastfeeding mammary glands [168,169]. Here, MUC1 is linked to breast benign neoplasm.